Does Hims Offer TRT? What Hims Actually Prescribes in 2026

Executive Summary

The most common misunderstanding in the Hims TRT question is that there is a single yes or no answer. As of early 2026, the answer is: Hims now offers two forms of testosterone support, but only one of them is true TRT, and neither is the injectable form most men mean when they search this question. Here is the exact breakdown of what Hims prescribes, updated for 2026.

Hims launched Kyzatrex — an FDA-approved oral testosterone undecanoate capsule taken twice daily — as an exclusive offering through a partnership with Marius Pharmaceuticals. Kyzatrex is genuine exogenous TRT: it delivers testosterone directly and raises serum levels the same way injections do, just through a different delivery mechanism. Hims also continues to offer enclomiphene, a SERM that stimulates your pituitary to produce more testosterone naturally. Enclomiphene is not TRT — it does not deliver exogenous testosterone. Injectable testosterone is explicitly not available on Hims as of early 2026, despite Hims announcing plans to introduce it.

If you are trying to decide whether Hims is the right platform for you, the critical variables are: whether you specifically want injections (Hims cannot help yet), whether your hypogonadism is primary or secondary (determines which Hims option is appropriate), and whether fertility preservation is a priority. Use compare TRT providers and Hims vs Roman vs Maximus to evaluate full alternatives.

At-a-Glance Comparison

Hims' 2026 testosterone offerings. Kyzatrex is FDA-approved exogenous TRT. Enclomiphene is a SERM, not TRT. Injectable testosterone is not yet available. Updated March 2026.

Kyzatrex: Hims' Oral TRT Option — What It Is and How It Works

Kyzatrex is the most important development in Hims' testosterone platform and the source of most current confusion. Kyzatrex (testosterone undecanoate) is an FDA-approved oral testosterone capsule taken twice daily with a fat-containing meal to optimize absorption. It is genuine, exogenous, FDA-approved testosterone replacement therapy — the same medical category as injections, just taken by mouth instead of by needle. Hims secured an exclusive partnership with Marius Pharmaceuticals to offer Kyzatrex through its platform, giving it a differentiated oral TRT product no other major telehealth platform offers. Buyers searching for does hims offer trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Kyzatrex works via a lymphatic absorption pathway that bypasses first-pass liver metabolism — a key improvement over older oral testosterone formulations (like methyltestosterone) that caused liver toxicity. Clinical studies show Kyzatrex normalizes testosterone in approximately 96% of patients with confirmed hypogonadism, with most men reaching mid-normal range within 2–4 weeks. The practical trade-offs versus injections: you take it twice daily with meals instead of injecting once or twice a week; blood levels are somewhat more variable between doses than the steady-state profile of testosterone cypionate injections; and the cost is typically higher than generic testosterone cypionate. Kyzatrex is appropriate for men with both primary and secondary hypogonadism — unlike enclomiphene, which only works for secondary. The candidate who gets the most from Kyzatrex is someone who wants confirmed TRT without needles, has no prior protocol experience, and is comfortable with the twice-daily oral routine. See testosterone delivery method comparison for a full breakdown of injection vs oral vs cream vs pellets and what each trade-off looks like clinically. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The most common patient complaint with Kyzatrex is the twice-daily meal requirement — absorption is meaningfully lower without dietary fat, which creates compliance challenges for men with irregular eating schedules. Also note: Kyzatrex typically costs more per month than generic testosterone cypionate injections, so the all-in cost is higher than injection-based TRT at other platforms. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Enclomiphene on Hims: What It Is, Who It Works For, and When It Fails

Enclomiphene is Hims' original testosterone product and still its most prescribed option. It is frequently confused with TRT — Hims markets both in the testosterone category and the onboarding flow does not always make the distinction immediately obvious. The mechanism is completely different: enclomiphene is a third-generation selective estrogen receptor modulator (SERM) that blocks estrogen receptors in the hypothalamus and pituitary, tricking those organs into increasing LH and FSH output, which signals the testes to produce more testosterone naturally. This is not exogenous testosterone. It does not suppress the HPT axis. It preserves sperm production. And it only works if your testes can actually respond to LH/FSH signaling. Buyers searching for does hims offer trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Enclomiphene is appropriate for men with secondary hypogonadism — where the pituitary-testicular axis is functional but underdriving testosterone production. In these men, enclomiphene can raise total testosterone by 100–200 ng/dL over 8–16 weeks with maintained or improved sperm parameters. Clinical studies (Repros Therapeutics Phase 3) showed consistent T increases while preserving normal sperm counts — the core advantage over exogenous TRT for men planning to conceive. Enclomiphene is not appropriate for men with primary hypogonadism — where the testes cannot respond to LH/FSH regardless of how much signaling they receive. Diagnosing which type you have requires LH and FSH on your lab panel. If your LH and FSH are already elevated (above range) and your testosterone is still low, your testes are not responding — enclomiphene cannot fix this, and Hims is the wrong platform. If you are unsure how to read your lab results, see how to read testosterone lab results for the full LH/FSH decision tree. For the full clinical comparison between enclomiphene and exogenous TRT, see enclomiphene vs TRT. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The highest-risk enrollment pattern on Hims is a man with primary hypogonadism who starts enclomiphene because of brand recognition, spends 12–16 weeks on it without seeing meaningful results, and only then discovers that his LH/FSH pattern means enclomiphene could never work for his diagnosis. Check LH and FSH before enrolling. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

The Injectable Testosterone Question: Why Hims Still Does Not Offer Injections in 2026

Multiple Hims news releases and investor communications announced plans to introduce injectable testosterone 'in 2026.' As of early March 2026, injectable testosterone is not available through Hims. Hims' own website FAQ explicitly states: 'No, Hims does not currently offer access to TRT injections.' This creates real confusion for men who read the 2025 announcements and assumed the launch had happened. Buyers searching for does hims offer trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

The planned injectable offering is testosterone cypionate or enanthate — the standard weekly-injection form used by Roman, Maximus, Defy Medical, and most specialist TRT clinics. When it launches, Hims' injectable TRT will position against Roman and Maximus on the platform advantages Hims already has: a large consumer brand, integrated pharmacy, and same-day or next-day prescription processing. The timing for injectable availability has not been publicly confirmed with precision — 'in 2026' remains the stated window. If injectable TRT is your specific requirement right now, Hims cannot serve you, and you should evaluate Roman, Maximus, or Defy Medical as alternatives. See Hims vs Roman vs Maximus for the full side-by-side comparison. See best online TRT clinics 2026 for a broader platform comparison. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Men who enroll with Hims expecting injectable TRT — based on the 2025 announcements — and then discover injections are not available will have to switch platforms, restart onboarding at a new provider, and potentially repeat the lab qualification process. This wastes 2–4 weeks and adds cost. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

How Hims Compares to Roman and Maximus for Testosterone Treatment in 2026

The Hims vs Roman vs Maximus comparison changed significantly when Hims added Kyzatrex. Previously, the distinction was clean: Hims = enclomiphene (SERM), Roman and Maximus = exogenous TRT. Now the picture is more nuanced: Hims offers two pathways — oral TRT via Kyzatrex and stimulation-based SERM therapy via enclomiphene — while Roman and Maximus offer injection-based TRT. This makes Hims a viable platform for a wider range of men than before, but still not the right choice for men who specifically want injections. Buyers searching for does hims offer trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

For men who want exogenous TRT and are open to oral delivery: Hims' Kyzatrex model is now a legitimate option, especially for needle-averse men. The platform advantage is brand integration — same provider for testosterone, ED, hair loss, and mental health — and Kyzatrex is the only major health platform exclusive for this product. The cost premium over generic injectable testosterone is real: expect $140–$220/month for Kyzatrex versus $100–$175/month for injectable cypionate at Roman or Maximus. For men who want injection-based TRT: Roman and Maximus are the two mid-market platforms. Maximus is typically preferred for men who want active protocol optimization and fertility-preserving hCG options; Roman is preferred for men who want straightforward onboarding with minimal friction. See how much does TRT cost for the full cost breakdown across all platforms. For men who want enclomiphene specifically: Hims is the largest consumer brand offering enclomiphene, but Maximus also offers enclomiphene, and specialist clinics like Defy Medical handle it with deeper monitoring. For the full enclomiphene clinic comparison, see best online enclomiphene clinics 2026. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: The primary risk in the Hims vs Roman vs Maximus comparison remains platform-diagnosis mismatch. Men with primary hypogonadism who enroll with Hims for enclomiphene see no results. Men who want injections and enroll with Hims for Kyzatrex discover the delivery method is different than expected. Knowing your LH/FSH and your delivery preference before choosing a platform eliminates both scenarios. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Who Hims Is and Is Not Right for in 2026: A Three-Question Decision Framework

With Hims' expanded offering, the platform is now appropriate for more men than before — but the diagnostic and preference variables that determine fit have also become more complex. This three-question framework gives you a clear answer before you start an intake form. Buyers searching for does hims offer trt usually start with a price question, but the stronger decision model is to evaluate clinical process quality, medication reliability, and support accountability at the same time. In telehealth programs, those three variables determine whether your first protocol can be sustained or has to be rebuilt after 60 to 90 days.

Question 1: Do you specifically want injectable testosterone? If yes, Hims cannot serve you yet. Go to Roman, Maximus, or Defy Medical. Question 2: What are your LH and FSH levels? If LH and FSH are elevated (above range) with low T, you have primary hypogonadism — Hims enclomiphene will not work, but Kyzatrex oral TRT will. If LH and FSH are low or normal with low T, you have secondary hypogonadism — both Hims options (enclomiphene and Kyzatrex) are viable. See primary vs secondary hypogonadism for the diagnostic guide. Question 3: Does fertility preservation matter? If yes and you have secondary hypogonadism, Hims enclomiphene is the most fertility-preserving option at this price point — it maintains the HPT axis and sperm production without suppression. If yes and you want exogenous TRT, Maximus' TRT + hCG protocol is the alternative. Read TRT and fertility for the full hCG and enclomiphene fertility comparison before deciding. For provider-level comparison across all options, see compare TRT providers. A practical way to lower decision regret is to document baseline labs, symptom goals, budget limits, and acceptable side-effect tolerance before enrollment. This turns provider conversations into comparable data points instead of marketing impressions. It also makes follow-up optimization faster because your care team can anchor every change to objective measurements and timeline milestones.

Common failure mode: Skipping the LH/FSH test before choosing between Hims' two options is the highest-probability route to a mismatched enrollment. Hims cannot legally conduct an LH/FSH test for free — require your provider to include it in your baseline panel and read the results before committing to enclomiphene versus Kyzatrex. Avoid that by using explicit check-ins at week 4, week 8, and week 12. If outcomes are under target and side effects are rising, escalate quickly or switch provider pathways instead of waiting for momentum to "self-correct."

Internal Resources to Compare Next

Use these pages to validate assumptions before spending. Cross-checking provider model details with treatment-specific pages is the fastest way to reduce preventable cost drift in month two and month three.

Compare Providers Before You Purchase

Hims now offers real TRT via Kyzatrex (oral tablet) and SERM-based testosterone support via enclomiphene — but injectable testosterone is not yet available. Your LH and FSH results determine which Hims option is clinically appropriate, or whether you need a platform like Roman or Maximus instead. Use our provider comparison tool to evaluate all your options with a side-by-side view before you enroll.

Disclosure: PeakedLabs may earn a commission from partner links. Editorial scoring and rankings remain independent.

Frequently Asked Questions

Does Hims offer TRT (testosterone replacement therapy)?

Yes, with nuance. Hims offers Kyzatrex — an FDA-approved oral testosterone capsule taken twice daily — which is exogenous TRT in pill form. Hims also offers enclomiphene, which is a SERM that stimulates natural testosterone production and is not TRT. Hims does NOT offer injectable testosterone as of early 2026, despite having announced plans to add it.

Does Hims offer testosterone injections?

No. As of early 2026, Hims does not offer injectable testosterone (testosterone cypionate, enanthate, or any other injectable form). Hims has publicly announced plans to add injectable testosterone in 2026, but it was not available at time of publication. Hims' own FAQ states: 'No, Hims does not currently offer access to TRT injections.' If you want testosterone injections now, evaluate Roman, Maximus Tribe, or Defy Medical instead.

What is Kyzatrex and is it real TRT?

Kyzatrex (testosterone undecanoate) is an FDA-approved oral testosterone capsule developed by Marius Pharmaceuticals. It is genuine exogenous testosterone — the same active compound as injectable testosterone cypionate, just delivered orally via a lymphatic absorption pathway that avoids liver metabolism. Clinical studies show approximately 96% of patients with confirmed hypogonadism reach normal testosterone levels on Kyzatrex. It is real TRT, not a supplement or SERM. The trade-off versus injections is cost (typically higher than generic testosterone cypionate) and the twice-daily meal requirement.

What is enclomiphene and is it TRT?

Enclomiphene is a SERM (selective estrogen receptor modulator) that stimulates your hypothalamus and pituitary to increase LH and FSH production, which then signals your testes to produce more testosterone naturally. It is not TRT — it does not deliver exogenous testosterone. The key implications: it preserves the HPT axis, maintains sperm production and fertility, and only works for men with secondary hypogonadism (functioning testes that are under-stimulated). For men with primary hypogonadism (non-functioning testes), enclomiphene does not work.

How do I know if I should choose Kyzatrex or enclomiphene on Hims?

The decision depends on your LH and FSH levels. If LH and FSH are elevated (above the normal range) and your testosterone is still low, you have primary hypogonadism — your testes cannot respond to LH/FSH signaling regardless. Enclomiphene will not work. Choose Kyzatrex oral TRT. If LH and FSH are low or normal with low testosterone, you have secondary hypogonadism — your pituitary is under-signaling. Both enclomiphene and Kyzatrex are viable. Fertility is the tiebreaker: if you are actively trying to conceive or want to preserve the option, enclomiphene maintains sperm production; Kyzatrex (like all exogenous TRT) suppresses sperm production during use.

Is Hims or Roman better for TRT?

It depends on what form of TRT you want. For oral TRT (Kyzatrex), Hims is the only platform with this exclusive offering. For injectable TRT (testosterone cypionate), Roman and Maximus are the two main mid-market options — Hims does not offer injections yet. For enclomiphene specifically (not TRT), Hims is the largest consumer platform for this treatment. If you want injectable TRT, Roman is the simpler onboarding experience; Maximus is the better choice for men who want at-home labs and performance-focused protocol management.

Does Hims preserve fertility while treating low testosterone?

Hims' enclomiphene pathway preserves fertility naturally — enclomiphene stimulates the HPT axis without suppressing it, maintaining LH, FSH, and sperm production during treatment. Kyzatrex, like all exogenous testosterone, suppresses the HPT axis and reduces sperm production during use. Unlike some platforms, Hims does not currently offer hCG as an add-on to Kyzatrex for fertility preservation while on exogenous TRT. If you want fertility-preserving exogenous TRT, Maximus (TRT + hCG) is the alternative. For a full fertility framework, read TRT and fertility.

How much does Hims testosterone treatment cost?

Hims enclomiphene runs approximately $99–$175/month for the medication plus lab costs (typically $75–$150 per draw at required monitoring intervals). Kyzatrex pricing on Hims has not been publicly standardized but typically runs $140–$220/month for the medication — higher than generic injectable testosterone at Roman or Maximus because Kyzatrex is a branded FDA-approved product. Total six-month all-in estimates: Hims enclomiphene approximately $800–$1,350; Hims Kyzatrex approximately $1,100–$1,700. See how much does TRT cost for full platform comparisons.

When will Hims offer injectable testosterone?

Hims announced injectable testosterone as planned for 2026 in its September 2025 investor communications. As of early March 2026, injections are not yet available. Hims has not published a specific launch date. The safest approach: check Hims' FAQ directly before enrolling if injections are your required delivery method, and do not assume they are live based on the 2025 announcements.

What labs does Hims require before prescribing testosterone treatment?

Hims requires baseline lab testing before prescribing either Kyzatrex or enclomiphene. At minimum expect: total testosterone, and typically free testosterone or SHBG, LH, FSH, and a CBC. The specific panel can vary by clinician and state. Get LH and FSH included regardless — those values are the most important inputs for determining whether Kyzatrex or enclomiphene is the appropriate pathway for your diagnosis.